Business
InMed Announces Results of 2023 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the \"Meeting\"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 27, 2023, were approved by the shareholders. A total of 1,292,647 common shares of the Company, representing approximately 38.84% of the Company's 3,328,191 issued and outstanding common shares, were represented in person or by proxy at the Meeting. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:\n\n\n\nDirector\nVotes For\n\nWithheld Votes\n\n\nNumber\nPercentage\n \nNumber\nPercentage\n\n\nEric A. Adams\n160,711\n76.09%\n\n50,513\n23.91%\n\n\nJanet Grove\n141,882\n67.17%\n\n69,342\n32.83%\n\n\nAndrew Hull\n141,398\n66.94%\n\n69,826\n33.06%\n\n\nNicole Lemerond\n145,865\n69.06%\n\n65,359\n30.94%\n\n\nBryan Baldasare\n145,659\n68.96%\n\n65,565\n31.04%\n\n\n\n \nInMed filed a report of voting results on SEDAR at www.sedarplus.ca on December 19, 2023.\nAbout InMed:\nInMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.\nInvestor Contact:\nColin Clancy\nVice President, Investor Relations\nand Corporate Communications\nT: +1.604.416.0999\nE: [email protected]\nCautionary Note Regarding Forward-Looking Information:\nThis news release contains \"forward-looking information\" and \"forward-looking statements\" (collectively, \"forward-looking information\") with...